LENZ Therapeutics (LENZ) Asset Utilization Ratio (2025 - 2026)

LENZ Therapeutics (LENZ) reported Asset Utilization Ratio of 0.02 for Q1 2026, up 23.27% quarter-over-quarter from 0.02 in Q4 2025.

LENZ Therapeutics (LENZ) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

LENZ Therapeutics (LENZ) has 2 years of Asset Utilization Ratio data on file, last reported at 0.02 in Q1 2026.

Asset Utilization Ratio for Q1 2026 came in at 0.02, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.02 (changed N/A YoY), and the FY2025 annual result was 0.02, changed N/A from the prior year.
Asset Utilization Ratio climbed to 0.02 in Q1 2026 per LENZ's latest filing, from 0.02 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.08 in Q3 2025 and troughed at 0.02 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	0.55
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.60
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	1,422.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	0.47
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	LENZ Therapeutics	192.19 Mn	192.19 Mn	825,000.00	0.02

Download Data